Online inquiry

IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5771MR)

This product GTTS-WQ5771MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5771MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11896MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ14963MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ4600MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ1108MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ11970MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ10474MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ6196MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ344MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1F5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW